Highly efficient and durable Th1-biased protective immunity from a novel mRNA vaccine against RSV via AI-assisted antigen screening

Key Points

• The mRNA vaccine generates significant Th1-biased immunity, which is crucial for protection against RSV.
• Findings indicate a remarkable duration of immunity, suggesting long-term protection benefits.
• Assessment includes AI-assisted antigen screening to enhance vaccine effectiveness against RSV.
• This early research calls for further development to confirm findings in larger and diverse populations.